Understanding the Trial Results
This trial tested a new treatment combination for patients with advanced non-small cell lung cancer (NSCLC) who did not respond well to previous therapies. The treatments used were:
- Sintilimab: A medication that helps the immune system fight cancer.
- Anlotinib: A pill that targets blood vessels to slow down tumor growth.
The goal was to see if using these two treatments together would be effective and safe for patients.
What Worked?
- About 17% of patients showed some improvement in their cancer (partial response).
- 65.5% had stable disease, meaning their cancer did not grow for a while.
- 82.8% of patients had some level of disease control, which is promising.
- The average time before the cancer worsened was about 5 months.
- The average survival time was around 15 months, with 44.8% of patients alive after 18 months.
What Didn’t Work?
- Only a small percentage of patients had a significant response to the treatment.
- Some patients experienced side effects, mainly high blood pressure, but no one stopped treatment because of these issues.
How Does This Help Patients or Clinics?
This combination treatment shows promise for patients with advanced lung cancer who have run out of options. It provides a new way to manage the disease when other treatments fail.
Opportunities for Hospitals and Doctors
- Consider using this treatment combination for patients who have not responded to PD-(L)1 inhibitors.
- Monitor patient responses closely to gather more data on effectiveness and safety.
- Participate in further clinical trials to explore this treatment’s potential.
Measurable Outcomes to Track
- Objective response rate (how many patients show improvement).
- Progression-free survival (how long patients live without cancer worsening).
- Overall survival rates (how long patients live after starting treatment).
- Side effects and their severity.
AI Tools to Consider
- AI systems can help track patient data and outcomes efficiently.
- AI can assist in predicting which patients might benefit most from this treatment.
Step-by-Step Plan for Clinics
- Start by reviewing patient eligibility for this treatment combination.
- Begin with a small group of patients to monitor responses and side effects.
- Collect data on patient outcomes to contribute to ongoing research.
- Gradually expand the use of this treatment as more data becomes available.
For more detailed information about this research, you can visit ClinicalTrials.gov.
